Table 4. Patients who received a second DAA treatment, by type of first regimen and HCV genotype (n = 72 patients).
| Second DAA Regimen |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| First DAA Regimen | SOF+DCV Number of patients (%) |
SOF+LDV Number of patients (%) |
Other Regimens | ||||||||
| N. patients 38 (52.7%) |
Gt1 | Gt2 | Gt3 | Gt4 | N. patients 27 (37.5%) |
Gt1 | Gt3 | Gt4 | N. patients 7 (9.7%) |
Gt1, Gt3, Gt4 | |
| SOF+RBV | 29 | 7* (24.1) | 3 (10.3) | 19* (65.5) | 14 | 11 (78.6) | 1(7.1) | 2(14.2) | 1 | PEG+SOF+RBV (Gt3) |
|
| SOF+SMV | 9 | 7 (77.8) | - | - | 2 (22.2) | 13 | 13* (100) | 2 | 3D (Gt1); 2D (Gt4) |
||
| SOF+LDV | - | - | - | - | - | - | - | - | - | 4 | 3D; (Gt1) SOF+SIM (Gt1 and Gt4) |
| SVR12 | 36 (94.7) |
13 (92.8) | 3 (100) |
18 (94.7) |
2 (100) |
26 (96.3) |
23 (95.8) |
1 (100) |
2 (100) |
8 (100) |
|
*1 patient Gt1 and 1 patient Gt3 did not achieved the SVR12 to the retreatment with SOF+DCV; 1 patient Gt1 did not achieved the SVR12 to the retreatment with SOF+LDV